Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05546151 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05546151 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants.
The verdict
NCT05546151, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of multiple ascending oral doses of BMS-986322 in healthy participants of Japanese descent.
Interventions
- DRUG BMS-986322
- OTHER Placebo for BMS-986322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2023-04-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05546151
The ClinicalTrials.gov registry entry for NCT05546151 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986322 is the first listed.
NCT05546151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05546151 about?
NCT05546151 is a clinical study titled "A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent". The purpose of this study is to assess the safety and tolerability of multiple ascending oral doses of BMS-986322 in healthy participants of Japanese descent.
What is the current status of trial NCT05546151?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-09-28. Estimated completion is 2023-04-07.
What interventions are being tested in trial NCT05546151?
The interventions under investigation include: BMS-986322 (DRUG), Placebo for BMS-986322 (OTHER).
Who is sponsoring clinical trial NCT05546151?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.